Literature DB >> 16153779

Inhibition of morphine tolerance by spinal melanocortin receptor blockade.

Katarzyna Starowicz1, Ilona Obara, Ryszard Przewłocki, Barbara Przewlocka.   

Abstract

Chronic use of morphine is accompanied by the development of morphine tolerance, which is one of the major problems associated with opiate treatment. Possible modulation of opioid effects by melanocortin receptor ligands has been recently demonstrated. Therefore, we investigated the influence of repeated intrathecal injection of a melanocortin receptor antagonist (SHU9119, JKC-363) on the development of morphine tolerance as measured by tail-flick test. It was also examined whether a single i.t. SHU9119 and JKC-363 administration could counteract the loss of analgesic potency of morphine in morphine tolerant rats. We examined also the influence of chronic morphine administration on mu-opioid receptor (MOR) and melanocortin 4 receptor (MC4-R) mRNAs in the rat spinal cord and dorsal root ganglia (DRG) during morphine tolerance. Morphine treatment (10mg/kg, i.p. twice daily) over 8 days induced tolerance as reflected by a significant reduction of withdrawal latency from 181 to 25% above baseline in the tail-flick test. Repeated co-administration of morphine and SHU9119 or JKC-363, significantly prevented the development of morphine tolerance. A single administration of an MC4-R antagonist restored morphine analgesic potency in morphine tolerant rats. Using RT-PCR we demonstrated no changes in the spinal cord but there was a decrease in MOR and increase in MC4-R gene expression in the DRG of rats tolerant to morphine. These results suggest that MC4-R may be involved in the mechanisms of opioid tolerance and antagonists of this receptor may be a possible new target in the search for strategies preventing the development of opioid tolerance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153779     DOI: 10.1016/j.pain.2005.07.003

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  16 in total

1.  Melanocortin-4 receptor expression in different classes of spinal and vagal primary afferent neurons in the mouse.

Authors:  Laurent Gautron; Charlotte E Lee; Syann Lee; Joel K Elmquist
Journal:  J Comp Neurol       Date:  2012-12-01       Impact factor: 3.215

2.  Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.

Authors:  James P Cain; Alexander V Mayorov; Minying Cai; Hui Wang; Bahar Tan; Kevin Chandler; YeonSun Lee; Ravil R Petrov; Dev Trivedi; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2006-08-22       Impact factor: 2.823

3.  Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice.

Authors:  Montserrat Navarro; Francisca Carvajal; Jose Manuel Lerma-Cabrera; Inmaculada Cubero; Mitchell J Picker; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2015-06-24       Impact factor: 3.455

Review 4.  Synaptic changes induced by melanocortin signalling.

Authors:  Vanni Caruso; Malin C Lagerström; Pawel K Olszewski; Robert Fredriksson; Helgi B Schiöth
Journal:  Nat Rev Neurosci       Date:  2014-02       Impact factor: 34.870

5.  Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice.

Authors:  Montserrat Navarro; Kendall L Luhn; Alexey B Kampov-Polevoy; James C Garbutt; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2019-03-19       Impact factor: 3.455

6.  Decreased mu-opioid receptor signalling and a reduction in calcium current density in sensory neurons from chronically morphine-treated mice.

Authors:  Emma E Johnson; Billy Chieng; Ian Napier; Mark Connor
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

7.  Melanocortin-4 receptor signaling in the central amygdala mediates chronic inflammatory pain effects on nociception.

Authors:  Nathan M Sharfman; Leslie K Kelley; Maria E Secci; Nicholas W Gilpin
Journal:  Neuropharmacology       Date:  2022-03-16       Impact factor: 5.273

8.  Opioid and melanocortin receptors: do they have overlapping pharmacophores?

Authors:  Yeon Sun Lee; Richard S Agnes; James P Cain; Vinod Kulkarni; Minying Cai; Christine Salibay; Kathy Ciano; Ravil Petrov; Alexander Mayorov; Josef Vagner; Dev Trivedi; Peg Davis; Shou-wu Ma; Josephine Lai; Frank Porreca; Ruben Vardanyan; Victor J Hruby
Journal:  Biopolymers       Date:  2008       Impact factor: 2.505

9.  Addiction and the adrenal cortex.

Authors:  Gavin P Vinson; Caroline H Brennan
Journal:  Endocr Connect       Date:  2013-05-31       Impact factor: 3.335

Review 10.  The melanocortin system as a potential target for treating alcohol use disorders: A review of pre-clinical data.

Authors:  José Manuel Lerma-Cabrera; Francisca Carvajal; James C Garbutt; Montserrat Navarro; Todd E Thiele
Journal:  Brain Res       Date:  2019-12-28       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.